



FINANCIAL TEAR SHEET

CORPORATE PROFILE

CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. Our multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Our lead program, CTX001, aims to treat Sickle cell disease and β -thalassemia using an ex vivo approach. We are also pursuing oncology indications with our allogeneic CAR-T platform and liver, lung, and neuromuscular indications using in vivo approaches. In addition, we have established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases with high unmet need. We have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from our scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. We are headquartered in Zug, Switzerland with R&D operations in Cambridge, Massachusetts, USA and select business operations in London, United Kingdom.

PRIMARY IR CONTACT


Chris Brinzey
 Westwicke Partners
Phone: 339-970-2843
E-mail:
chris.brinzey@westwicke.com

STOCK PERFORMANCE

CRSP (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$52.96
Change (%)	▲ 0.86 (1.65%)
Volume	745,687
52 Week Low	\$13.50
Market Cap	\$2,114,856,121
Rolling EPS	-1.56
PE Ratio	0
Shares Outstanding	40,592,248

Data as of 03/23/18 4:00 p.m. ET



RECENT HEADLINES & EVENTS

	Date	Title
Mar-08-2018 - 4:15 p.m. CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results	03/27/18	CRISPR Therapeutics at Guggenheim Conference on Disruptive Technologies in Immuno-Oncology
Feb-21-2018 - 8:31 a.m. CRISPR Therapeutics to Participate in Four Upcoming Investor Conferences	03/28/18 3:30 p.m. ET	CRISPR Therapeutics at 17th Annual Needham Healthcare Conference
Feb-08-2018 - 4:32 p.m. CRISPR Therapeutics Announces Transition of Bill Lundberg, MD		

SEC FILINGS

Filing Date	Form
03/14/18	4
03/09/18	4
03/09/18	4
03/09/18	4

Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources